ALMS

AlumisB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$45.00

+60.8% vs current

Most likely

Base case

50%

Probability

Target price

$30.00

+7.2% vs current

B-

Bear case

25%

Probability

Target price

$12.00

-57.1% vs current

AI sentiment snapshot

Latest data as of 2026-06-06

AI commentary

Lean positive on the long-term TYK2 package but cautious on timing. The primary-source 8-K is constructive on clinical efficacy, cash runway, and upcoming milestones, yet the deterministic prior is negative across the next 5d-120d window, which argues for a monitoring stance rather than a chased-up breakout call. Secondary post-print analyst coverage was upbeat, but that only partially offsets the binary SLE/NDA risk and thin near-term commercialization evidence [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].

RankAlpha Sentiment Codex - 2026-06-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-14eventQ1 2026 results kept the lead asset on trackHigh impact

The May 14 company update reaffirmed positive Phase 3 psoriasis data, a favorable safety/tolerability profile, and $569.5M of cash/cash equivalents/marketable securities that management says funds operations into 4Q27 [#SEC-8K-2026-05-14].

2026-09-15eventPotentially pivotal SLE topline in 3Q 2026High impact

The LUMUS Phase 2b systemic lupus erythematosus readout remains the key franchise-broadening event beyond psoriasis and is still guided for 3Q26 [#SEC-8K-2026-05-14].

2026-10-31catalystUnified TYK2 franchise expansionHigh impact

Alumis said it is evaluating additional indications under a unified TYK2 franchise strategy and expects more updates later in 2026, which could widen the long-duration market opportunity if the current data package holds [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-06 • Updated nightlySource: Internal modelMethodology